Gilead’s Twice-Yearly Medication Shows Success In Preventing HIV, But Cost Criticized

By Luke Zarzecki / July 25, 2024 at 3:44 PM

Gilead Sciences’ twice-yearly injectable medication for HIV prevention passed a Phase 3 clinical trial with flying colors after demonstrating 100% efficacy and zero infections, the company announced at an international meeting Wednesday (July 24).

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.

FEATURES

NEWSLETTERS

ABOUT US

Inside Health Policy is a subscription-fee-based daily digital news service from Inside Washington Publishers.

SITE LICENSES

Economical site license packages are available to fit any size organization, from a few people at one location to company-wide access. For more information on how you can get greater access to Inside Health Policy for your office, contact Online Customer Service at 703-416-8505 or healthpolicy@iwpnews.com.

STAY CONNECTED

Gilead’s Twice-Yearly Medication Shows Success In Preventing HIV, But Cost Criticized

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.